Glutaraldehyde inactivation of enveloped DNA viruses in the preparation of haemoglobin-based oxygen carriers
Source abstract
Abstract
Glutaraldehyde (GA), used medically as a disinfectant and as a crosslinker for haemoglobin (Hb)-based oxygen carriers (HBOCs), was investigated for its ability to inactivate viruses during the preparation of these artificial blood substitutes. Porcine parvovirus (PPV; a non-enveloped DNA virus) and porcine pseudorabies virus (PRV; an enveloped DNA virus) were used as the virus indicators. Upon treatment with 0.1 mM GA, the titer of PRV decreased from 9.62 log10 to 2.62 log10 within 0.5 h, whereas that of PPV decreased from 7.00 log10 to 2.30 log10 in 5 h. Following treatment with 1.0 mM GA, the titer of PRV decreased from 11.00 log10 to 1.97 log10 within 0.5 h, whereas that of PPV decreased from 7.50 log10 to 3.43 log10 in 4.5 h. During the polymerization of Hb with GA, the GA concentration decreased to 1.0 and 0.1 mM within 30 and 50 min, respectively, at a GA:Hb molar ratio of 10:1, whereas at a GA:Hb molar ratio of 30:1, GA decreased to those same concentrations in 1.5 and 2.5 h, respectively. This rapid decrease in GA concentration during its polymerization with Hb indicates that GA must be added into the Hb solution in a short time in order to get as high a initial concentration as possible. In this study, the GA can only inactivate PRV effectively, given that a longer time (4.5 h) was required for it to inactivate the PPV titer. This study therefore demonstrates that GA inactivates the enveloped DNA virus only during the preparation of HBOCs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Virus-based gene therapy research · Mechanical Circulatory Support Devices
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
,
National Engineering Research Center for Miniaturized Detection System, Xi’an, P.R. China
References (36)
Show source-provided references
1. 10.3390/jfb801001110.3390/jfb8010011 ↗
2. 10.1080/1073119060058023110.1080/10731190600580231 ↗
3. 10.1111/j.1423-0410.2004.00530.x10.1111/j.1423-0410.2004.00530.x ↗
4. 10.1007/BF0187742210.1007/BF01877422 ↗
5. 10.1038/srep4592210.1038/srep45922 ↗
6. 10.1016/j.vetmic.2016.11.01910.1016/j.vetmic.2016.11.019 ↗
7. 10.1016/j.antiviral.2017.01.00310.1016/j.antiviral.2017.01.003 ↗
8. Tsutomu U Tetsuhiro K Junya K inventor; Tctkk U assignee. Virus-inactivated hemoglobin and method of producing the same. Japan patent US WO/2006/003926; 2006.
9. 10.1007/s10527-008-9035-y10.1007/s10527-008-9035-y ↗
10. 10.3109/1073119920911966310.3109/10731199209119663 ↗
11. Sofer G. Virus inactivation in the 1990s – and into the 21st century: Part 4. Culture media, biotechnology products, and vaccines. Biopharm Int. 2003;1:50–57.
12. 10.1562/0031-8655(2000)071<0090:VPISFH>2.0.CO;210.1562/0031-8655(2000)071<0090:VPISFH>2.0.CO;2 ↗
13. 10.1248/bpb.24.41810.1248/bpb.24.418 ↗
14. 10.1292/jvms.14-062510.1292/jvms.14-0625 ↗
15. 10.1007/978-1-62703-733-4_2610.1007/978-1-62703-733-4_26 ↗
16. 10.1111/trf.1361910.1111/trf.13619 ↗
17. 10.1128/CDLI.4.5.504-508.199710.1128/CDLI.4.5.504-508.1997 ↗
18. Brown F. An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines. Dev Biol Stand. 1991;75:37–41.
19. 10.1631/jzus.2006.B066010.1631/jzus.2006.B0660 ↗
20. 10.3390/biom701000210.3390/biom7010002 ↗
21. 10.1111/jam.1338410.1111/jam.13384 ↗
22. 10.1016/j.vaccine.2017.01.00310.1016/j.vaccine.2017.01.003 ↗
23. 10.1016/j.febslet.2012.04.04710.1016/j.febslet.2012.04.047 ↗
24. Rausch CW Gawryl MS Houtchens RA inventor; Biopure Corporation assignee. Method for producing a stable polymerized hemoglobin blood-substitute. United States Patent US 5 955 581; 1999.
25. 10.1021/bp049872l10.1021/bp049872l ↗
26. Yan KP, Jing XD, Jing H, et al. Detection of residual glutaraldehyde in hemoglobin-based oxygen carrier with high performance liquid chromatography. Chin J Anal Chem. 2009;37:1515–1518 (Chinese).
27. 10.1128/JVI.00022-1110.1128/JVI.00022-11 ↗
28. 10.1021/bp049974b10.1021/bp049974b ↗
29. 10.1002/bit.2145910.1002/bit.21459 ↗
30. 10.1046/j.1365-2672.1999.00791.x10.1046/j.1365-2672.1999.00791.x ↗
31. 10.1080/21691401.2016.126363910.1080/21691401.2016.1263639 ↗
32. 10.1081/BIO-12003783010.1081/BIO-120037830 ↗
33. 10.7205/MILMED-D-12-0040810.7205/MILMED-D-12-00408 ↗
34. Kluger R, Lui FE. HBOCs from chemical modification of Hb. In: Kim HW, Greenburg AG, editors. Hemoglobin-based oxygen carriers as red cell substitutes and oxygen therapeutics. New York (NY): Springer Berlin Heidelberg; 2014. p. 159–183.
35. 10.1080/21691401.2017.132868510.1080/21691401.2017.1328685 ↗
36. Abraham TJ, Palamiappan R, Dhevendaran K. Inactivation of luminous Vibrio spp. by free chlorine. Bangladesh J Fish Res. 2002;6:53–58.